Heat Biologics

$1.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+3.64%) Today
+$0.01 (+0.88%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Heat Biologics and other stocks, options, and ETFs commission-free!

About HTBX

Heat Biologics, Inc. Common Stock, also called Heat Biologics, is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. The listed name for HTBX is Heat Biologics, Inc. Common Stock.

CEO
Jeff A. Wolf
Employees
36
Headquarters
Morrisville, North Carolina
Founded
2008
Market Cap
182.22M
Price-Earnings Ratio
Dividend Yield
Average Volume
5.74M
High Today
$1.18
Low Today
$1.10
Open Price
$1.11
Volume
6.02M
52 Week High
$4.30
52 Week Low
$0.195

Collections

HTBX Earnings

-$0.19
-$0.13
-$0.06
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 30, Pre-Market

You May Also Like